ArticleCureus2026
Individualised N-terminal Pro-B-type Natriuretic Peptide Thresholds for the Diagnosis of Heart Failure: A Proof-of-Concept Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Heart failure (HF) is underdiagnosed in the community. N-terminal pro-B-type natriuretic peptide (NT-proBNP) has variable sensitivity for HF across different subgroups, particularly for HF with preserved ejection fraction (HFpEF). We calculated individualised NT-proBNP thresholds with 90% sensitivity for the detection of HF, adjusted for age and comorbidities. We investigated whether individualised thresholds had greater sensitivity for the detection of HF, and whether adverse event rates were similarly low in patients with NT-proBNP levels below individualised and fixed thresholds. Methods A total of 1320 patients were recruited from a prospective clinical cohort referred for cardiovascular magnetic resonance (CMR). The diagnostic performance of individualised and fixed NT-proBNP thresholds for detecting HF was compared. The associations between individualised thresholds and the primary composite outcome of first HF hospitalisation or cardiovascular death were investigated. Results Individualised NT-proBNP thresholds ranged from 31 to 2295 pg/ml. Individualised thresholds were more sensitive for the detection of all HF (0.90; 0.80 for 125 pg/ml; 0.55 for 400 pg/ml), HFpEF (0.87; 0.74 for 125 pg/ml; 0.43 for 400 pg/ml), and HF with reduced ejection fraction (0.98; 0.94 for 125 pg/ml; 0.83 for 400 pg/ml) and achieved a high sensitivity of ~0.90 in all patient subgroups. Individualised thresholds associated with adverse outcomes (hazard ratio and 95% confidence interval 6.88 (3.04-15.60)). Patients with NT-proBNP levels below individualised thresholds and a fixed threshold of 125 pg/ml had similarly low event rates. Conclusions Individualised NT-proBNP thresholds, optimised for increased sensitivity, may inform future investigation in community settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.